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Abstract 
The coronavirus disease 2019 (COVID-19) was first detected in December 
2019 in Wuhan, China. So far, 136 reports from the WHO were reported. In 
the latest report, 6416828 patients in almost all countries have been infected 
with COVID-19. The present study discusses the different aspects of 
COVID such as emergence, signs and symptoms, comparisons with SARS 
and MERS, concerns, governments' actions in controlling the virus, and a 
descriptive analysis of the spread and death. The emergence of the 
coronavirus family in the last two decades has created a public health issue 
around the world. It has also caused serious damages to the infrastructure, 
economy, culture, and communities of countries. Thus, affected 
governments have taken steps to reduce these concerns such as quarantine, 
education, traffic control, closure of recreational centers, reduction of 
working hours, etc. Despite strict measures to contain the COVID-19, this 
virus is still expanding and the question of "what actions should be taken 
with what political package?" is being asked. To answer this question, it is 
important to understand the process of disease occurrence, and modeling 
different interventions on changing the natural course of the disease are very 
important. 
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Introduction 
The coronavirus disease 2019 (COVID-19) was first 
detected in December 2019 in Wuhan, China (1). The 
COVID-19 was originally known as the 2019 novel 
coronavirus (2019-nCoV), but on 11 February 2020, 
the World Health Organization (WHO) named it 
COVID-19 (2). So far, 136 reports from the WHO have 
been reported. In the latest report, 6416828 patients in 




The first epidemic of coronaviruses goes back 
to November 2002 where the virus severe acute 
respiratory syndrome (SARS) coronavirus was 
identified in southern China (Guangdong province) 
(3). This virus killed 774 patients (out of 8448 cases) 
in 37 countries (4, 5). Other types of coronavirus such 
as the Middle East respiratory syndrome (MERS) was 
identified in 2012 in Saudi Arabia and South Korea (6). 
MERS coronavirus was transmitted directly and 
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indirectly through dromedary camels to humans, 
although the mode of transmission remains unclear. 
More than 36% of cases of those diagnosed with 
MERS symptoms died (360 deaths out of 983 cases) 
(7). 
 
The rise of coronavirus in humans: in November 
2002 in Guangdong, China SARS coronavirus was 
transmitted to humans via an animal virus from an 
uncertain animal whose speculation is more on bats 
(8). In recent studies, evidence of an almost identical 
genetic structure for the cave-dwelling horseshoe bats 
and SARS coronavirus has been found (9-13). This 
virus has spread to the palm civets (Asian civet cat) 
through the cave-dwelling horseshoe bats and then to 
humans (14). According to the Chinese Ministry of 
Health, one of the factors contributing to the spread of 
the SARS virus is the lack of transparent 
communication (2). At the end of the epidemic, 6.8% 
of patients younger than 60 years were at risk of fatality 
(15). About 9 years later, a new type of coronavirus 
known as MERS with symptoms including fever, 
cough, and shortness of breath was observed in a 60-
year-old man in Jeddah, Saudi Arabia (16). Although 
MERS coronavirus is a beta coronavirus from bats, 
evidence suggests that MERS is transmitted from 
dromedary camel to human (17, 18). Interestingly, 
studies have shown that camels have immunity against 
MERS coronavirus, therefore, the reason for the 
camel-to-human transmission remains unclear (7, 18-
20). It was reported that approximately 36% of patients 
were at risk of fatality from MERS (7). At the end of 
2019, the third coronavirus that was very close to 
SARS was identified (21). COVID-19 is thought to 
have an animal origin like SARS and MERS (22). The 
outbreak of this infectious disease was identified in 
December 2019 at Huanan Seafood Wholesale Market 
with several animal-to-human zoonotic events and then 
in January 2020, early signs of human-to-human 
transmission were observed (23). As of 18th of March 
2020, over 150 countries have been infected with the 
COVID-19. 
 
Different signs, symptoms, and clinical features: the 
clinical symptoms of SARS and MERS are almost 
similar, with a slight difference. SARS and MERS 
have an incubation period of 7 and 5.5 days, 
respectively, and these diseases develop in 95% of 
cases after 13 days (24, 25). In contrast, COVID-19 has 
an incubation period between 2 to 10 days, and the 
median disease develops after 12 days (26, 27). Table 
1 summarizes all symptoms observed in SARS, 
MERS, and COVID-19 based on the severity of 
symptoms (24, 25, 28-31).  
 
Survival in the environment: Since the transmission 
of this type of virus is high (especially for COVID-19), 
it is imperative to understand the survival of this virus 
in the environment. An important feature of the 
coronavirus is its ability to survive in the environment 
(32). The simplest mode of transmission is direct 
contact with an infected person, exposure to infectious 
droplets, and touching surfaces infected with the virus 
(5, 33). In classifying the virus' survival in the 
environment, COVID-19 has a longer half-life than 
SARS and MERS (34). According to studies, 
coronavirus has high viability in cold weather, 
therefore, at high temperatures (30-40°C), it loses its 
stability (27, 35). Table 2 summarizes the coronavirus 
survival in different environments (27, 36-38). 
 
Concerns: Following the outbreak of SARS, MERS, 
and COVID-19 in the last two decades, and the lack of 
a specific treatment, a major public health issue has 
occurred worldwide (39, 40). SARS and MERS viruses 
with low transmission rates and high case-fatality 
(6.8% and 30%, respectively) were not very common 
in humans. But COVID-19 with low case-fatality 
(6.0%: 382867 deaths out of 6416828 patients) and 
high transmission rates (outbreaks in almost all 
countries in several months) was rapidly transmitted 
between Chinese cities and other countries around the 
world (25, 41). The power of COVID-19 transmission 
in late 2019 and early 2020 has created palpable fear 
and stress among people (42). Studies have shown that 
stress hurts immune function (43-45). Therefore, fear 
and stress because of this epidemic is the first global 
concern. Other coronavirus concerns include the 
shortage of personal protective equipment, panic 
buying, rising demand, and hoarding, which put 
people’s lives at risk (46).  
Governments’ preventive actions towards virus 
inhibition: as a result of the widespread outbreak of 
COVID-19, affected countries have adopted strategies 
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to prevent the further spread of the virus. The top six 
countries with the highest number of infected cases in 
six WHO regions are the USA, Russian, India, Iran, 
China, and South Africa, respectively. Also, the 
country with high case fatality was the United 
Kingdom. In these countries, government strategies 
aimed at containing the virus include city quarantine, 
home quarantine, self-care, information sharing, 
closure of schools and colleges, canceling concerts and 
sporting events, airport screening, and traffic and 
border controls. In other countries, actions such as 
regular hand washing, the use of disposable gloves, 
Table 1: Classification of symptoms of SARS, MERS and COVID-19. 
Signs and symptoms SARS  MERS  COVID-19 
Fever Common symptom Common symptom Common symptom 
Cough Common symptom Common symptom Common symptom 
Shortness of breath Less common symptom Less common symptom Common symptom 
Myalgia or fatigue Common symptom Common symptom Common symptom 
Abnormal chest X-
rays 
Common symptom Common symptom Common symptom 
Upper airway 
congestion 
Rare symptom Rare symptom Less common symptom 
Muscle pain − − Less common symptom 
Headache Common symptom Common symptom Less common symptom 
Confusion Less common symptom Less common symptom Less common symptom 
Sputum production − − Less common symptom 
Sore throat − − Rare symptom 
Haemoptysis  Less common symptom Less common symptom Rare symptom 
Rhinorrhea − − Rare symptom 
Chest pain Rare symptom Rare symptom Rare symptom 
Diarrhea Less common symptom Less common symptom Rare symptom 
Nausea  Less common symptom Less common symptom Common symptom during 
incubation period 
Chill  Common symptom Common symptom Less common symptom 
 
Table 2: Coronavirus survival in different environments. 
Surface SARS coronavirus MERS coronavirus COVID-19 coronavirus 
Paper 24 hours − − 
Disposable gown 2 days at room 
temperature 
− − 
Cotton gown 24 hours − − 
Respiratory samples 5 days at room 
temperature 
− − 
Stool Few days at room 
temperature 
− − 
Faecal droplet 4 to 5 days − − 
Plastic  24 hours at 30 °C 48 hours at 20 °C 9 days at room temperature 
Steel  24 hours at 30 °C 48 hours at 20 °C − 
Metal 5 days − 9 days at room temperature 
Glass  4 days − 9 days at room temperature 
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hair covering, eye protection, and wearing isolation 
gowns and masks are also being pursued (47). 
Summaries of the strategies implemented in the above 
countries with the highest number of cases are 
presented in Table 3 (48-58). 
Reports published by WHO 
So far, 136 reports (as of 4th June 2020) have been 
released by the WHO (59). According to the reports, 
the initial outbreak of Covid-19 began from China and 
in a few months, almost all countries around the world 
were infected. In their latest report, the numbers of 
confirmed infected cases in six WHO regions 
(European region [EURO], Eastern Mediterranean 
region [EMRO], Western Pacific region [WPRO], 
American region [AMRO], South-East Asia region 
[SEARO] and African region [AFRO]) were 2211148, 
570026, 186853, 3022824, 309597, and 115639, while 
the center of infection in these areas are Russian, Iran, 
China, USA, India, and South Africa, respectively. 
We used the WHO reported the number of 
infected people to estimate the trend of COVID-19 in 
six regions. According to reports in six regions, the 
trend of infection in two regions namely EURO, 
AMRO and were faster (Figure 1A).  In the EURO, the 
slope of confirmed cases had risen sharply from 20th 
March to 4th June. But in the AFRO, from 20th March 
to 4th June, the trend had slight changes. Also in death 
trend in the two regions (EURO and AMRO) had a 
sharp slope rather than the other regions (Figure 1B). 
The case fatality of six WHO regions was 
presented in Figure 2. In this Figure, the case fatality 
of COVID-19 in EURO are higher than in other 
regions (Figure 2A). So, in the USA, China, and Iran, 
from 16th April to 4th June, the trend for case fatality 
had high dramatically. But in other regions, the trend 
for case fatality increased slowly (Figure 2B). 
Table 3: COVID-19 control strategies implemented in the top countries in six WHO regions with the highest number 
of infections. 
                                      Countries 
Strategies 
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Prohibition of visiting patients         
 
Preventing the entry of tourists 

















Information sharing         
 
Managing the spread of rumors         
 
Closing recreational centers         
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Publications: thousands of articles have been 
published in various journals. Our report here only 
included the PubMed search engine with (COVID-19 
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/Abstract]) OR (COVID-19 [MeSH Terms]) OR 
(Novel coronavirus [MeSH Terms]) search strategy 
until 12 March 2020. Of this search, 38 studies were in 
Chinese languages and full text not existing. 
Furthermore, 37 studies with information about 
COVID-19 were included in this review. From these 
37 studies, there were 4277 confirmed cases (55.2% 
male and 44.8% female). From 1766 infected patients, 
44.2%, 48.9%, and 1.8% were older, middle-aged, and 
young, respectively. Common symptoms in all cases 
were fever (85.2%) and cough (57.6%). Also in 1836 
patients, 763 (41.6%), 503 (27.4%), 461 (25.1%) and 
140 (7.6%) had mild (<37.3℃), moderate (37.3-38℃), 





In the present study, we provided information on the 
outbreak, transmission, symptoms, differences, and 
treatments for the three types of coronavirus (SARS, 
MERS, and COVID). Coronavirus belongs to the 
coronavirus family which is common between 
mammals and birds (93). In 2002, the first type of 
virus, SARS, was transmitted to humans through palm 
civets. SARS was dramatically inhibited over one year 
due to the high fatality rate and low transmission rate. 
In July 2003, the SARS pandemic was declared to be 
over (24). However, 9 years after, a new virus (MERS) 
from the same family as SARS appeared. MERS was 
transmitted from the dromedary camel to humans and 
led to the death of 36% of infected patients (7). 
Transmission of the MERS from human to human has 
been through close and prolonged contact. Basic 
programs aimed at combatting the spread of MERS 
include educational programs. MERS and SARS are 
almost similar in signs, symptoms, and clinical 
features, however, fatalities and delayed innate 
antiviral response of these two viruses are very 
different (6). In late 2019, the novel coronavirus 
(COVID-19) emerged from China and spread 
throughout the world and by March 16, 2020, it had 
affected more than 150 countries. Although COVID-
19 also belongs to the coronavirus family, it has a much 
higher transmission and low fatalities (nearly 6.0%) 
than SARS and MERS. Unlike SARS and MERS, 
COVID-19 is associated with shortness of breath and 
rarely has chill symptoms.  
The rapid outbreak of COVID-19 has created 
worldwide concerns that can be categorized into two 
levels. First, the power of COVID-19 transmission in 
several months has created fear and stress among 
people. Therefore, immune system function may be 
negatively affected in these conditions, and in case of 
infection by the virus, the immune system may not 
work properly, leading to a possible increase in fatality 
rate (94). Secondly, the shortage of personal protective 
equipment as a result of panic buying, rising demand, 
and hoarding put people’s lives at risk. Therefore, 
affected governments have taken steps to reduce these 
concerns such as notification, quarantine, self-care, 
education, traffic control, closure of some training and 
recreation centers, reduction of working hours, and so 
on.  
So far, 132 situation reports have been 
published by the WHO. Daily reports on the total 
number of confirmed cases and deaths by affected 
countries, the spread of infection, newly infected 
countries, and the epidemic curve are also provided. As 
of 18th March 2020, more than a thousand confirmed 
cases of COVID-19 have been reported in fifteen 
countries. China, Italy, and Iran have a faster rate of 
infection in the last two weeks. In China, following a 
decision to control body temperature at stations and 
airports, monitoring public places, public health 
surveillance, quarantine, and build specialized 
hospitals, the number of infections has dropped to less 
than thirty after about two months (95). But in Italy, 
despite restrictive measures such as air traffic from 
China and quarantine (96), the number of people 
infected with the COVID-19 has increased and in the 
latest WHO reports, the number of infected cases was 
441108. In Iran, due to US sanctions, the health sector 
has faced serious problems in providing protective 
clothing, necessary treatments, and COVID-19 
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detection equipment, which undoubtedly affects the 




Conclusion    
Currently, the COVID-19 epidemic is considered one 
of the most important global health challenges and has 
spread to almost all countries worldwide. This has 
caused serious negative effects on infrastructure, 
economy, culture, and communities of countries. 
Moreover, despite strict measures to contain the 
COVID-19, this virus is still expanding and the 
question of "what actions should be taken with what 
political package?" is being asked. To answer this 
question, understanding the process of disease 
occurrence and modeling different interventions on 
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